Cordis Announces Acquisition of MedAlliance, Positioning Itself for Market Leadership in Drug-Eluting Balloon Technology
prnewswire.com
news
2022-10-18 13:00:00

MIAMI LAKES, Fla., Oct. 18, 2022 /PRNewswire/ -- Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technologies, today announced its acquisition, subject to customary closing conditions including regulatory approvals, of MedAlliance, a Switzerland-based company at the forefront of transformative drug-eluting balloons. By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR™ (Sustained Limus Release) drug-eluting balloon.
